Replies to post #15498 on ScripsAmerica Inc. (SCRCQ)

[coolerheadsprevail]

Alleyba says.................

...........he essentially agrees with your position and you have to admit that the revenue streams are being set in motion starting with China and the Tn. plant.

RE: Tennessee, although growing, revenues are nowhere close to where they need to be yet in relation to any other revenue source SCRC may have to enable SCRC to be in a position to stop issuing new convertible debt. SCRC needs to bring on additional headcount in the salesforce ASAP to accelerate the revenue growth in this area.

RE: China, this is a puzzle wrapped inside an enigma. Nowhere in SCRC's history did they ever mention Hong Kong. It was always specifically China and the thousands of pharmacies and hospitals spread throughout the provinces in mainland China. SCRC alleged to have travelled to China, not to Hong Kong. SCRC issued forwar-looking statements about getting into Walmart China, Carrefour, and RT Mart International, along with other retail distribution outlets specifically in mainland China. Much fanfare was made by SCRC and its paid promoters about China's loosening of its 1-child policy. Much hype was made by SCRC and its paid promoters of mainland China's $32B OTC market. Much talk by SCRC was about being in the process of being approved by regulators in mainland China.

A "typical" 60-90 day approval timeframe was heavily touted. Even beyond the high-end of this time window extending beyond 90-days, we suddenly hear about Hong Kong approval -- but nary a peep about China, the crown jewel of not only Asia but of the world from a consumer population perspective???

And now we get a poster who refers to SCRC in the first person claiming that SCRC is just now "translating" docs and using the HK registration process as a roadmap to apply for registration for China???

Don't get me wrong, HK is great as it represents a start, but it is not in the same league as mainland China. Not even close. And the new explanation by someone claiming to be working on the registration process for SCRC that SCRC's business model in Asia is now centered around the bootleg market of the small segment of mainland China residents who visit HK to haul suitcases of RapiMeds back to the mainland?

Seriously. I pray that mainland China approval is near completion and that the delay is attributable to the Lunar celebration. That being said, the longer this thing goes w/o a formal statement about the status of China approval, the less plausible the Lunar celebration becomes as an excuse.

Registration and regulatory approval is nice, but it does not translate to revenues. We need the other shoe to drop. We need announcements that SCRC has signed a distribution agreement with a major pharmacy chain or other retail chain, with hopefully some high level disclosures on the financial terms so that the Street can have a barometer by which to measure and value SCRC properly. What we don't need is an announcement that 3 foreign nationals from mainland China each bought 12 packs of RapiMeds in Hong Kong and are ferrying them back to the mainland.

In my opinion we are now a real company and CEO will not be giving out any more paper.

SCRC has always been a real company. But it is going thru the trials and tribulations of trying to be one of the few companies that graduate from simply being a real company to being a real big company.

That being said, I respectfully disagree that SCRC has stopped entering into new dilutive convertible debt agreements as well as issuing new restricted shares for any variety of services. To have stopped doing so would necessitate a sufficient enough cash flow to cover ALL of SCRC's operating and SG&A expenses. I don't see revenues sufficient enough to satisfy this cash need. If you do, please enlighten me with actual numbers as to where all this cash is currently coming from? The 10-K will be an interesting read, that's for sure. I would love to be wrong on this, but the math simply doesn't add up at this current time.

[Cats83]

"We also have PIMD and we forgot about that stream...so when I get the feeling we are done with paper than I begin to feel good that the price of the stock is undervalued here and think it has room to double or triple without any real bumps in the road.."

This is an excellent point Alleyba. I believe PIMD will far outperform our expectations this year. Go SCRC!!